＜Research＞Nomura Raises HANSOH PHARMA (03692.HK) TP to$17.23, Expects Interim Profit to Soar 86%

　　Nomura released a report raising the TP of HANSOH PHARMA (03692.HK) -0.400 (-2.250%) Short selling $19.35M; Ratio 36.487% from $15.03 to $17.23, while maintaining a Neutral rating. Nomura also raised the revenue and profit forecasts for 2024 by 2.7% and 6.9% respectively, and for 2025 by 6% and 0.7% respectively, reflecting that the revenue performance of the antibody-drug conjugate (ADC) in 1H and the progress of Almonertinib within expectations offset the sales pressure of generic drugs.

　　The broker said its current price is equivalent to the forecast P/E ratio of 24.6x and 26.5x for 2024 and 2025 respectively, and estimated the 1H revenue and earnings to rise by 38.2% and 86.1% YoY.

　　(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-22 16:25.)

　　Related NewsCICC: Re-entry Into High Div. Theme Should Wait Until Sufficient Pullback; Prefers Semiconductors/ Autos/ Medias/ Softwares/ Biotechs in Short Term

　　AAStocks Financial News